Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

CPX-351 is a liposomal formulation of cytarabine:daunorubicin designed to deliver synergistic drug ratios to leukemia cells. In this phase 2 study, newly diagnosed older acute myeloid leukemia (AML) patients were randomized 2:1 to first-line CPX-351 or 7+3 treatment. The goal was to determine effica...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin S., Kovacsovics, Tibor J., Damon, Lloyd E., Komrokji, Rami, Solomon, Scott R., Kolitz, Jonathan E., Cooper, Maureen, Yeager, Andrew M., Louie, Arthur C., Feldman, Eric J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2014
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4624448/
https://ncbi.nlm.nih.gov/pubmed/24687088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-12-540971
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky